Ohtsuka Kenji, Sato Akihiko, Kawaguchi Satoshi, Hashimoto Masato, Suzuki Yasuo
Department of Ophthalmology, Sapporo Medical University, School of Medicine, Hokkaido, Japan.
Jpn J Ophthalmol. 2002 Sep-Oct;46(5):563-7. doi: 10.1016/s0021-5155(02)00544-0.
To evaluate the effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.
We selected 41 Japanese patients (age range, 21-76 years; mean = 49 years) who had active Graves' ophthalmopathy among 205 consecutive patients examined at Sapporo Medical University Hospital between 1997 and 1999. In a prospective study, we investigated the effect on the 41 patients of high-dose intravenous methylprednisolone pulse therapy (1 g/day x 3 days x 3 times) followed by 3-month oral prednisone therapy. Coronal computed tomography (CT) of the orbit, exophthalmometry and monocular fixation field measured by Goldmann perimetry were carried out before the steroid pulse therapy, and 1 and 6 months after the steroid pulse therapy. The maximum coronal section area of the rectus muscle in each eye was measured using an orbital CT image.
Extraocular muscle hypertrophy was significantly reduced 1 and 6 months after the pulse therapy (paired t-test, P <.01), and was not significantly different between 1 and 6 months after the pulse therapy. Proptosis was not significantly reduced by the pulse therapy. Monocular fixation fields were measured in 34 patients with diplopia, and limitation of eye movements was improved in 15 patients (44%) by the pulse therapy. In the other patients, improvement of the limitation was not detectable by the test of the monocular fixation field.
The treatment in this study is effective for extraocular muscle hypertrophy, and relapse was minimum within 6 months. However, this treatment has limited effect on limitation of eye movements and less effect on proptosis.
评估大剂量静脉注射类固醇脉冲疗法继以3个月口服类固醇疗法对格雷夫斯眼病的疗效。
我们从1997年至1999年在札幌医科大学医院接受检查的205例连续患者中,挑选出41例患有活动性格雷夫斯眼病的日本患者(年龄范围21 - 76岁,平均49岁)。在一项前瞻性研究中,我们调查了大剂量静脉注射甲泼尼龙脉冲疗法(1克/天×3天×3次)继以3个月口服泼尼松疗法对这41例患者的疗效。在类固醇脉冲疗法前、疗法后1个月和6个月进行眼眶冠状位计算机断层扫描(CT)、眼球突出度测量以及用戈德曼视野计测量单眼注视视野。使用眼眶CT图像测量每只眼睛直肌的最大冠状截面积。
脉冲疗法后1个月和6个月,眼外肌肥大明显减轻(配对t检验,P <.01),且脉冲疗法后1个月和6个月之间无显著差异。脉冲疗法未使眼球突出明显减轻。对34例复视患者测量了单眼注视视野,脉冲疗法使15例患者(44%)的眼球运动受限情况得到改善。在其他患者中,通过单眼注视视野检查未发现眼球运动受限情况有所改善。
本研究中的治疗方法对眼外肌肥大有效,且6个月内复发率最低。然而,该治疗方法对眼球运动受限的效果有限,对眼球突出的效果较差。